HAT-r-ACC - Efficacy and safety of fexinidazole in patients with Human African Trypanosomiasis (HAT) due to Trypanosoma brucei rhodesiense: a multicentre, open-label clinical trial

A vector-borne parasitic illness, human African trypanosomiasis (HAT), also known as sleeping sickness, is usually fatal without treatment. The less  prevalent form, T.b. rhodesiense (r-HAT), is concentrated in East Africa, with Malawi and Uganda reporting 88% of all cases worldwide between…

03.09.2018 - 02.09.2023
Clinical Trial
European Commission (EU) / European & Developing Countries Clinical Trials Partnership (EDCTP2)
Medicines Implementation Research Unit
Aita Signorell